11 November2026: MindRank and BoomRay partner to develop AI-driven Cyclic Peptide Radioligand Conjugates for oncology
Hangzhou MindRank Technology and Suzhou BoomRay Pharma announced a strategic research collaboration to jointly develop AI-driven radioligand conjugates using cyclic peptides as targeting ligands, with the objective of discovering first-in-class candidates for oncology diagnostics and therapeutics
Under the collaboration, MindRank will leverage its AI-driven drug discovery platform to design, screen and optimize cyclic peptide ligands, while BoomRay will contribute its expertise in radiopharmaceutical development, radiolabeling and clinical translation to advance the resulting candidates. The partnership will follow an iterative AI-design, experimental-validation and feedback approach to accelerate ligand discovery and optimization
The collaboration aims to address limitations in existing targeted radiopharmaceutical approaches, particularly the need for improved tumor targeting, higher tumor uptake and reduced exposure to normal tissues. Cyclic peptides offer potential advantages over full-length antibodies, including smaller molecular size, faster tumor penetration, tunable clearance and more cost-effective synthesis, making them attractive targeting ligands for RDC development
MindRank will deploy its proprietary Intera life-science foundation model, including InteraFold-PEP, to predict cyclic peptide–target protein binding modes and optimize ligand affinity and selectivity. BoomRay will use its radiopharmaceutical capabilities to translate these AI-designed ligands into RDC candidates, with potential applications in both diagnostic imaging and targeted radionuclide therapy through a theranostic approach
Strategically, the collaboration brings together AI-enabled molecular design and radiopharmaceutical development to establish a discovery platform for next-generation cyclic peptide-based RDCs. For BoomRay, the partnership complements its existing radiopharmaceutical pipeline, which includes the cyclic peptide-based Nectin-4-targeted BRP-020 program, while providing access to AI-driven ligand discovery capabilities